Skip to main content

Mesenchymal tumors of the stomach: radiologic and pathologic correlation


Mesenchymal tumors of the stomach are uncommon, with gastrointestinal stromal tumor (GIST) being the most common among them. Majority of the tumors may arise from cells of Cajal, smooth muscle cells, neural cells, totipotent stem cells, adipocytes or fibroblasts. Imaging plays an important role not only in staging but also in characterizing these tumors. Many of these tumors have characteristic imaging features. GISTs usually present as large cavitating and necrotic tumors with exophytic component. Presence of fat tissue within the tumor suggests a lipoma or a teratoma, early phase hyperenhancement indicates glomus tumor and hemangioma, and delayed contrast enhancement is seen in schwannoma. Their differentiation from epithelial tumors like carcinoma and neuroendocrine tumors is often possible based on the location (mesenchymal tumors are intramural), spread, morphological appearance and enhancement patterns. However, overlapping features exist between these tumors with imaging often being only suggestive. A biopsy is necessary for a definitive diagnosis in many cases.

Graphical abstract

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12


  1. Strandring S (2016). Abdominal oesophagus and stomach. In: Strandring S (Ed). Gray’s anatomy-the anatomical basis of clinical practice. 41st edition. Elsevier Limited, New York. pp 1111–1123.

  2. Strandring S (2016). Development of the peritoneal cavity, gastrointestinal tract and its adnexae. In: Strandring S (Ed). Gray’s anatomy-the anatomical basis of clinical practice. 41st edition. Elsevier Limited, New York. pp 1048–1068.

  3. WHO Classification of tumors editorial board (2019). Mesenchymal tumors of the digestive system. In: Digestive system tumors: WHO classification of tumors. 5th Edition. Chapter 12. pp 433–498.

  4. Kang HC, Menias CO, Gaballah AH, et al (2013). Beyond the GIST: mesenchymal tumors of the stomach. Radiographics. 33:1673–1690.

  5. Nagpal P, Prakash A, Pradhan G, et al (2017). MDCT imaging of the stomach: advances and applications. Br J Radiol. 90:20160412.

  6. Sheybani A, Menias CO, Luna A, et al (2015). MRI of the stomach: a pictorial review with a focus on oncological applications and gastric motility. Abdom Imaging. 40:907–930.

  7. Wong CS, Gong N, Chu Y-C, et al (2012). Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV. Eur J Radiol 81:2122–2126.

  8. Schmidt S, Dunet V, Koehli M, et al (2013). Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT. Acta Radiol 54:837–842.

  9. Rubin BP, Heinrich MC, Corless CL (2007). Gastrointestinal stromal tumour. Lancet 369:1731–1741.

  10. Kindblom LG, Remotti HE, Aldenborg F, et al (1998). Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259–1269.

  11. Zhao X, Yue C (2012). Gastrointestinal stromal tumor. J Gastrointest Oncol 3:189–208.

  12. Burkill GJC, Badran M, Al-Muderis O, et al (2003). Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 226:527–532.

  13. Li FP, Fletcher JA, Heinrich MC, et al (2005). Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 23:2735–2743.

  14. Miettinen M, Fetsch JF, Sobin LH, et al (2006). Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 30:90–96.

  15. Carney JA. (1999) Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clinic proceedings Mayo Clinic 74:543–552.

  16. Bartolotta TV, Taibbi A, Galia M, et al (2006) Gastrointestinal stromal tumour: 40- row multislice computed tomography findings. Radiol Med 111: 651–660.

  17. Sandrasegaran K, Rajesh A, Rushing DA, et al (2005). Gastrointestinal stromal tumors: CT and MRI findings. Eur Radiol 15:1407–1414.

  18. Marrari A, Wagner AJ, Hornick JL (2012). Predictors of response to targeted therapies for gastrointestinal stromal tumors. Arch Pathol Lab Med 136:483–489.

  19. Varshney VK, Gupta RK, Saluja SS, et al (2019). Analysis of clinicopathological and immunohistochemical parameters and correlation of outcomes in gastrointestinal stromal tumors. Indian J Cancer. 56:135–143.

  20. Miettinen M, Lasota J, Sobin LH (2005). Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 29:1373–1381.

  21. Miettinen M, Fletcher CDM, Kindblom LG, Tsui WMS (2010). Mesenchymal tumors of the stomach. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumors of the digestive system. 4th. ed. Lyon: IARC. pp 74–79.

  22. Ibrahim A, Chopra S (2020). Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors. Arch Pathol Lab Med 144:655–660.

  23. Casali PG, Blay JY (2010). Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 Suppl 5:v98–102.

  24. National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma V.2.2009. Fort Washington, PA: NCCN; 2009.

  25. Cerski MR, Pereira F, Matte US, et al (2011). Exon 11 mutations, Ki67, and p16(INK4A) as predictors of prognosis in patients with GIST. Pathol Res Pract 207:701–706.

  26. Zhou Y, Hu W, Chen P, et al (2017). Ki67 is a biological marker of malignant risk of gastrointestinal stromal tumors: A systematic review and meta-analysis. Medicine (Baltimore) 96:e7911.

  27. Fletcher CD, Berman JJ, Corless C, et al (2002). Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33: 459–465.

  28. Miettinen M, Lasota J (2006). Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol 23:70–83.

  29. Joensuu H (2008). Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39:1411–1419.

  30. Gold JS, Gönen M, Gutiérrez A, et al (2009). Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: A retrospective analysis. Lancet Oncol 10:1045–1052.

  31. Joensuu H, Vehtari A, Riihimäki J, et al (2012). Risk of recurrence of gastrointestinal stromal tumour after surgery: An analysis of pooled population-based cohorts. Lancet Oncol 13:265–274.

  32. Agaimy A (2010). Gastrointestinal stromal tumor (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. Int J Clin Exp Pathol 3:461–471.

  33. Schmieder M, Henne-Bruns D, Mayer B, et al (2016). Comparison of Different Risk Classification Systems in 558 Patients with Gastrointestinal Stromal Tumors after R0-Resection. Front Pharmacol. 7:504.

  34. Chen T, Ye LY, Feng XY, et al (2019). Performance of risk stratification systems for gastrointestinal stromal tumors: A multicenter study. World J Gastroenterol 25:1238–1247.

  35. Li Y, Chen X, Ma X, Lu X (2022). Computed tomography in the size measurement of gastric gastrointestinal stromal tumors: Implication to risk stratification and "wait-and-see" tactics. Eur J Surg Oncol S0748–7983(22)00008–7.

  36. Mazzei MA, Cioffi Squitieri N, Vindigni C, et al (2020). Gastrointestinal stromal tumors (GIST): a proposal of a "CT-based predictive model of Miettinen index" in predicting the risk of malignancy. Abdom Radiol (NY) 45:2989–2996.

  37. Tirumani SH, Shinagare AB, Jagannathan JP, Krajewski KM, Ramaiya NH, Raut CP (2014). Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection. Eur J Surg Oncol 40:420–428.

  38. Ren C, Wang S, Zhang S (2020). Development and validation of a nomogram based on CT images and 3D texture analysis for preoperative prediction of the malignant potential in gastrointestinal stromal tumors. Cancer Imaging 20:5.

  39. Yu MH, Lee JM, Baek JH, Han JK, Choi BI (2014). MRI features of gastrointestinal stromal tumors. AJR Am J Roentgenol 203:980–991.

  40. Song Y, Li J, Wang H, et al (2021). Radiomics Nomogram Based on Contrast-enhanced CT to Predict the Malignant Potential of Gastrointestinal Stromal Tumor: A Two-center Study. Acad Radiol S1076–6332(21)00220–8.

  41. Zhao Y, Feng M, Wang M, Zhang L, Li M, Huang C (2021). CT Radiomics for the Preoperative Prediction of Ki67 Index in Gastrointestinal Stromal Tumors: A Multi-Center Study. Front Oncol 11:689136.

  42. Tirumani SH, Jagannathan JP, Krajewski KM, Shinagare AB, Jacene H, Ramaiya NH (2013). Imatinib and beyond in gastrointestinal stromal tumors: a radiologist’s perspective. AJR Am J Roentgenol 201:801–810.

  43. Abdulkader I, Cameselle-Teijeiro J, Forteza J (2005). Pathological changes related to imatinib treatment in a patient with a metastatic gastrointestinal stromal tumour. Histopathology 46:470–472.

  44. Choi H, Charnsangavej C, de Castro Faria S, et al (2004). CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183:1619–1628.

  45. Dimitrakopoulou-Strauss A, Ronellenfitsch U, Cheng C, et al (2017). Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review. Clin Transl Imaging 5:183–197.

  46. Loughrey MB, Mitchell C, Mann GB, et al (2005). Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J Clin Pathol 58:779–781.

  47. Pauwels P, Debiec-Rychter M, Stul M, et al (2005). Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology 47:41–47.

  48. Weledji EP, Enoworock G, Ngowe MN (2014). Gastric leiomyosarcoma as a rare cause of gastric outlet obstruction and perforation: a case report. BMC Res Notes 7:479.

  49. Kang WZ, Xue LY, Tian YT (2019). Leiomyosarcoma of the stomach: A case report. World J Clin Cases 7:3575–3582.

  50. Yamamoto H, Handa M, Tobo T, et al (2013). Clinicopathological features of primary leiomyosarcoma of the gastrointestinal tract following recognition of gastrointestinal stromal tumours. Histopathology 63:194–207.

  51. Hasnaoui A, Jouini R, Haddad D, et al (2018). Gastric leiomyosarcoma and diagnostic pitfalls: a case report. BMC Surg 18:62.

  52. Garg R, AlRajjal A, Berri R, Barawi M (2020). Primary Gastric Leiomyosarcoma: a Case Report and Review of the Literature. J Gastrointest Cancer 51:335–340.

  53. Kim SJ, Kim WS, Cheon JE, et al (2009). Inflammatory myofibroblastic tumors of the abdomen as mimickers of malignancy: imaging features in nine children. AJR Am J Roentgenol 193:1419–1424.

  54. Wang Y, Shen L, Yun T, Zhu C, Wang P, Wang S (2021). Clinicopathological features of gastric inflammatory myofibroblastic tumor: Report of five cases. Exp Ther Med 22:948.

  55. Lee JE, Choi SY, Lee HK, et al (2018). Computed tomographic features of inflammatory myofibroblastic tumour of the stomach in adult patients: An analysis of five multicentre cases with literature review. J Med Imaging Radiat Oncol 62:769–776.

  56. Tan H, Wang B, Xiao H, Lian Y, Gao J (2017). Radiologic and Clinicopathologic Findings of Inflammatory Myofibroblastic Tumor. J Comput Assist Tomogr 41:90–97.

  57. Horger M, Pfannenberg C, Bitzer M, et al (2005). Synchronous gastrointestinal and musculoskeletal manifestations of different subtypes of inflammatory myofibroblastic tumor: CT, MRI and pathological features. Eur Radiol 15:1713–1716.

  58. Coffin CM, Hornick JL, Fletcher CD (2007). Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 31:509–520.

  59. Coffin CM, Humphrey PA, Dehner LP (1998). Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey. Semin Diagn Pathol 15:85– 101.

  60. Cook JR, Dehner LP, Collins MH, et al (2001). Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: A comparative immunohistochemical study. Am J Surg Pathol 25:1364–1371.

  61. Bongiovi JJ, Dufly JL, Healdow E (1967). Gastric hemangioma associated with upper gastrointestinal bleeding. Arch Surg 95:93–95.

  62. Basbug M, Yavuz R, Dablan M, Baysal B, Gencoglu M, Yagmur Y (2012). Isolated cavernous hemangioma: a rare benign lesion of the stomach. J Clin Med Res 4:354–357.

  63. Zong L, Chen P, Shi GH, Wang L (2011). Gastric cavernous hemangioma: A rare case with upper gastrointestinal bleeding. Oncol Lett 2:1073–1075.

  64. Attash SM, Ali MS, Al-Nuaimy HA (2012). Isolated cavernous haemangioma of the stomach in a 3-year-old child: an unusual cause of upper GI bleeding. BMJ Case Rep 2012:bcr2012006979.

  65. Schlecht I, Hierholzer J, Maurer J, Mau H, Stobbe H, Felix R (1999). Gastric haemangioma: a rare cause of gastrointestinal bleeding. Pediatr Radiol 29:63.

  66. Park SH, Han JK, Kim TK, et al (1999). Unusual gastric tumors: radiologic-pathologic correlation. Radiographics 19:1435–1446.

  67. Thompson WM, Kende AI, Levy AD (2003). Imaging characteristics of gastric lipomas in 16 adult and pediatric patients. AJR Am J Roentgenol 181:981–985.

  68. Sullivan IW, Hota P, Dass C (2019). Gastric lipomas: a case series and review of a rare tumor. BJR Case Rep 5:20180109.

  69. Voltaggio L, Murray R, Lasota J, Miettinen M (2012). Gastric schwannoma: a clinicopathologic study of 51 cases and critical review of the literature. Hum Pathol 43:650–659.

  70. Levy AD, Quiles AM, Miettinen M, Sobin LH (2005). Gastrointestinal schwannomas: CT features with clinicopathologic correlation. AJR Am J Roentgenol 184:797–802.

  71. Liu J, Chai Y, Zhou J, Dong C, Zhang W, Liu B (2017). Spectral Computed Tomography Imaging of Gastric Schwannoma and Gastric Stromal Tumor. J Comput Assist Tomogr 41:417–421.

  72. Takeda M, Amano Y, Machida T, Kato S, Naito Z, Kumita S (2012). CT, MRI, and PET findings of gastric schwannoma. Jpn J Radiol 30:602–605.

  73. Karabulut N, Martin DR, Yang M (2002). Case report: gastric schwannoma: MRI findings. Br J Radiol 75:624–626.

  74. Cairo MS, Grosfeld JL, Weetman RM (1981). Gastric teratoma; unusual cause for bleeding of the upper gastrointestinal tract in the newborn. Pediatr 67:721–724.

  75. Parvin S, Sengupta M, Mishra PK, Chatterjee U, Banerjee S, Chaudhuri MK (2016). Gastric teratoma: A series of 7 cases. J Pediatr Surg 51:1072–1077.

  76. Saleem M, Mirza B, Talat N, Sharif M (2018). Gastric teratoma: Our 17 year experience. J Pediatr Surg 53:234–236.

  77. Gupta DK, Srinivas M, Dave S, Agarwala S, Bajpai M, Mitra DK (2000). Gastric teratoma in children. Pediatr Surg Int 16:329–332.

  78. Valenzuela-Ramos MC, Mendizábal-Méndez AL, Ríos-Contreras CA, Rodríguez-Montes CE (2010). Pediatric gastric teratoma. J Radiol Case Rep 4:6–13.

  79. Sharma A, Arora R, Gupta R, Dinda AK (2010). Immature gastric teratoma in an infant: report of a case and review of the literature. Indian J Pathol Microbiol 53:868–870.

  80. Norris HJ, Zirkin HJ, Benson WL (1976). Immature (malignant) teratoma of the ovary. A clinical and pathologic study of 58 cases. Cancer 37:2359–2372.

  81. Morgan BK, Compton C, Talbert M, Gallagher WJ, Wood WC (1990). Benign smooth muscle tumors of the gastrointestinal tract. A 24-year experience. Ann Surg 211:63–66.

  82. Xu JX, Ding QL, Lu YF, Fan SF, Rao QP, Yu RS (2021). A scoring model for radiologic diagnosis of gastric leiomyomas (GLMs) with contrast-enhanced computed tomography (CE-CT): Differential diagnosis from gastrointestinal stromal tumors (GISTs). Eur J Radiol 134:109395.

  83. Wang J, Zhou X, Xu F, Ao W, Hu H (2021). Value of CT Imaging in the Differentiation of Gastric Leiomyoma From Gastric Stromal Tumor. Can Assoc Radiol J 72:444–451.

  84. Yang HK, Kim YH, Lee YJ, et al (2015). Leiomyomas in the gastric cardia: CT findings and differentiation from gastrointestinal stromal tumors. Eur J Radiol 84:1694–1700.

  85. Greenson JK (2003). Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. Mod Pathol 16:366–375.

  86. Debol SM, Stanley MW, Mallery S, Sawinski E, Bardales RH (2003). Glomus tumor of the stomach: cytologic diagnosis by endoscopic ultrasound-guided fine-needle aspiration. Diagn Cytopathol 28:316–321.

  87. Liu KL, Wang HP, Tseng WY, Shun CT, Chen SJ, Tsang YM (2005). Glomus tumor of the stomach: MRI findings. AJR Am J Roentgenol 185:1190–1192.

  88. Toti L, Manzia TM, Roma S, et al (2019). Rare malignant glomus tumor of the stomach with liver metastases. Radiol Case Rep 14:463–467.

  89. Fang HQ, Yang J, Zhang FF, Cui Y, Han AJ (2010). Clinicopathological features of gastric glomus tumor. World J Gastroenterol 16:4616–4620.

  90. Wang J, Liu C, Ao W, et al (2020). Differentiation of gastric glomus tumor from small gastric stromal tumor by computed tomography. J Int Med Res 48:300060520936194.

  91. Hur BY, Kim SH, Choi JY, et al (2011). Gastroduodenal glomus tumors: differentiation from other subepithelial lesions based on dynamic contrast-enhanced CT findings. AJR Am J Roentgenol. 197:1351–1359.

  92. Kinowaki Y, Abe S, Abe S, et al (2021). Synovial sarcoma of the stomach: a case report and a systematic review of literature. Clin J Gastroenterol 14:1020–1026.

  93. Hu S, Wong K, Ramesh KH, Villanueva-Siles E, Panarelli N, In H (2019). Diffuse, Aggressive Metastatic Progression after Minimally Invasive Local Resection of Primary Gastric Synovial Sarcoma: a Case Report and Systematic Review of the Literature. J Gastrointest Cancer 50:116–122.

  94. Kuboyama Y, Yamada Y, Kohashi K, et al (2021). Three cases of synovial sarcoma of gastric wall: A case report and review of the literature. Pathol Res Pract 219:153352.

  95. Banito A, Xiang Li L, Aimee N, et al (2018). The SS18-SSX oncoprotein hijacks KDM2B-PRC1.1 to drive synovial sarcoma. Cancer Cell 34:346–348.

  96. Lu Q, Wang K, Liu D, et al (2017). Stomach desmoid tumor: a case report and review of the literature. Int J Clin Exp Pathol 10:10531–10538.

  97. Lee JC, Thomas JM, Phillips S, Fisher C, Moskovic E (2006). Aggressive fibromatosis: MRI features with pathologic correlation. AJR Am J Roentgenol 186:247–254.

  98. Harima H, Kimura T, Hamabe K, et al (2018). Invasive inflammatory fibroid polyp of the stomach: a case report and literature review. BMC Gastroenterol 18:74.

  99. Yang MX, Zhao ZH, Yang JF, et al (2017). Imaging findings of gastric plexiform fibromyxoma with a cystic change: A case report and review of literature. Medicine (Baltimore) 96:e8967.

Download references


No sources of funding.

Author information

Authors and Affiliations



Idea for the article—KSM. Literature search and data analysis—KSM, PD Initial draft and critical revision of the work—KSM, PD.

Corresponding author

Correspondence to Kumble Seetharama Madhusudhan.

Ethics declarations

Conflict of interest

No conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Madhusudhan, K.S., Das, P. Mesenchymal tumors of the stomach: radiologic and pathologic correlation. Abdom Radiol 47, 1988–2003 (2022).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Mesenchymal tumor
  • Gastric tumors
  • Gastrointestinal stromal tumor
  • Leiomyoma
  • Leiomyosarcoma
  • Inflammatory myofibroblastic tumor